MK-2866 vs Testosterone for weight loss
Short answer: For weight loss, users rate them about the same: 89% report improvement with MK-2866 (80 reports) and 93% with Testosterone (45 reports).
MK-2866 has 0 meta-analyses and 0 randomized trials on PubMed; Testosterone has 75 and 125.
Based on 612 reports about MK-2866 and 822 about Testosterone. Not medical advice.
| MK-2866 SARM | Testosterone Medication | |
|---|---|---|
| User score | 33 | 54 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 39% | 77% |
| Reports | 612 | 822 |
| Research | DResearch: None | AResearch: Strong |
| Meta-analyses / RCTs | 0 / 0 | 75 / 125 |
| Mainly used for | ||
| Weight loss % reporting improvement | 89% (80) | 93% (45) |
| Appetite % reporting improvement | 62% (8) | — |
| Focus % reporting improvement | 71% (7) | 82% (28) |
| Energy % reporting improvement | 54% (37) | 92% (76) |
| Sleep % reporting improvement | 20% (20) | 79% (19) |
| Anxiety % reporting improvement | 33% (9) | 80% (25) |
| Mood % reporting improvement | 63% (49) | 88% (104) |
| Memory % reporting improvement | — | 100% (2) |
| Performance % reporting improvement | 88% (192) | 97% (149) |
| Recovery % reporting improvement | 97% (60) | 91% (23) |
| Pain & inflammation % reporting improvement | 70% (27) | 67% (6) |
| Libido % reporting improvement | 31% (45) | 93% (70) |
| Hormones % reporting improvement | 4% (82) | 90% (91) |
| Heart & lipids % reporting improvement | 0% (8) | 62% (8) |
| Skin & hair % reporting improvement | 33% (6) | 40% (5) |
| Longevity % reporting improvement | — | 50% (2) |
| Common side effects | suppression, fatigue, insomnia, headache | suppression, hair loss, acne, water retention |
| Typical dose reported | Not listed | 200 mg / weekly |
MK-2866Full MK-2866 profile →
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
TestosteroneFull Testosterone profile →
Latest review conclusion
The guidelines also provide recommendations regarding identification of patients, dosing, monitoring, and follow-up. This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in postmenopausal women.
Menopause, 2023 ↗What a user said
“Feel the best I've ever felt in my life. TRT and peptides have been game changers for me!”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate